Target intelligence / Profile preview

Solute carrier family 25 member 19 (SLC25A19)

Target
SLC25A19
Molecular classification
Transporter, Solute carrier family, Mitochondrial inner membrane carrier
01

Overview

Solute carrier family 25 member 19 (SLC25A19) is a mitochondrial transporter protein embedded in the inner mitochondrial membrane. It primarily functions as the mitochondrial thiamine pyrophosphate (ThPP) carrier, importing ThPP into the mitochondrial matrix. This transport is essential for the activity of ThPP-dependent enzymes, such as the α-ketoglutarate dehydrogenase complex, which is vital for mitochondrial energy metabolism in the citric acid (Krebs) cycle. Genetic loss-of-function mutations in SLC25A19 cause devastating metabolic diseases, including Amish lethal microcephaly—characterized by severe congenital microcephaly, α-ketoglutaric aciduria, and neonatal lethality due to impaired mitochondrial function and abnormal brain development[1][2][4][6]. The protein was previously thought to function as a deoxynucleotide carrier, but its primary physiological role is now recognized as ThPP transport[2][6]. No drugs are currently known to target SLC25A19 directly.

Other names
DNCDNC_HUMANMCPHAMitochondrial deoxynucleotide carrierhMTPPT
02

Mechanism of action

Not applicable; no known drugs with a defined mechanism of action targeting SLC25A19 transporter.

03

Biological functions

Mitochondrial thiamine pyrophosphate transportMitochondrial metabolism (citric acid/Krebs cycle)Support of activity for α-ketoglutarate dehydrogenase complexSupport of brain development
04

Disease associations

Neurodevelopmental diseaseInherited metabolic disorder (Amish lethal microcephaly)Leigh syndromePotential role indicated in cancer (colon cancer, metabolic diseases)
05

Safety considerations

Mutational loss causes severe, lethal neurodevelopmental disease (Amish lethal microcephaly)No data on risks/concerns from pharmacologic targeting, as no drugs are approved or in trials for this transporter
06

Biomarkers

Mutations (such as Gly177Ala and Q192H) serve as biomarkers for Amish lethal microcephalyPossible utility in genetic diagnosis of thiamine metabolism disorders

Beyond the preview

Go deeper on Solute carrier family 25 member 19 (SLC25A19).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 25 member 19 (SLC25A19).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call